Patients with aggressive B-cell lymphoma are considered for anti-CD19 CAR-T when they have stable or progressive lymphoma after second-line chemotherapy, relapse after ASCT, or require a third-line therapy [8]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.